EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges

Vitor Alfredo de Santana Silva, Katarine Gabriely Aurista do Nascimento, Priscila Gubert, Maria G Carneiro-da-Cunha, Kátia Alves Ribeiro, Paulo Antônio Galindo Soares iD

ACS Pharmacology & Translational Science · 12.12.2025 · 8 (12) · 4214-4236

DOI: 10.1021/acsptsci.5c00521 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 18.11.2025. Verfasst von Vitor Alfredo de Santana Silva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry/Keizo Asami Institute-iLIKA, Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego, s/n, Cidade Universitária, CE…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funda??o de Amparo ? Ci?ncia e Tecnologia do Estado de Pernambuco, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoarthritis (OA) is a leading cause of physical disability, psychological distress, and a significant economic burden worldwide. Current treatments alleviate symptoms; however, disease progression remains largely uncontrolled, highlighting the urgent need for investigation of disease-modifying therapies. Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), such as glucosamine (GlcN), chondroitin sulfate (CS), and hyaluronic acid (HA), have gained increasing attention for their potential benefits in alleviating pain and mitigating the inflammatory and degenerative processes that characterize OA. These compounds modulate several homeostatic mechanisms, promoting anti-inflammatory, antioxidant, antiapoptotic, and anabolic countermensuring effects. Nevertheless, debates regarding their long-term efficacy and safety remain controversial, which explains why major osteoarthritis societies do not provide the same recommendations for the pharmacological treatment of OA. In this context, this review critically evaluates the current evidence surrounding HA, GlcN, and CS, highlighting their safety, mechanisms of action, and promising therapeutic perspectives for modifying the natural course of knee, hand, and hip OA.

Schlagwörter

Stichwörter der Autor:innen

chondroitin sulfateglucosaminehyaluronic acidinflammation

Autor:innen und Institutionen

  • Department of Biochemistry/Keizo Asami Institute-iLIKA, Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego, s/n, Cidade Universitária, CEP: 50670-420 Recife, Pernambuco, Brazil.
  • Postgraduate Program in Biology Applied to Health, PPGBAS, Federal University of Pernambuco, CEP: 50670-901 Recife, Pernambuco, Brazil.

ORCID-Profile: Paulo Antônio Galindo Soares

Förderung

  • Funda??o de Amparo ? Ci?ncia e Tecnologia do Estado de Pernambuco
  • Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
  • Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior

Zitieren

APA

Silva, V. A. S., Aurista do Nascimento, K. G., Gubert, P., Carneiro-da-Cunha, M. G., Ribeiro, K. A., & Soares, P. A. G. (2025). Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges. ACS Pharmacology & Translational Science, 8(12), 4214-4236. https://doi.org/10.1021/acsptsci.5c00521

Vancouver

Silva VAS, Aurista do Nascimento KG, Gubert P, Carneiro-da-Cunha MG, Ribeiro KA, Soares PAG. Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges. ACS Pharmacology & Translational Science. 2025;8(12):4214-4236. doi:10.1021/acsptsci.5c00521

BibTeX
@article{Silva2025,
  author = {Silva, Vitor Alfredo de Santana and Aurista do Nascimento, Katarine Gabriely and Gubert, Priscila and Carneiro-da-Cunha, Maria G and Ribeiro, Kátia Alves and Soares, Paulo Antônio Galindo},
  title = {Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges},
  journal = {ACS Pharmacology & Translational Science},
  year = {2025},
  volume = {8},
  number = {12},
  pages = {4214--4236},
  doi = {10.1021/acsptsci.5c00521}
}
Kostenlos starten →